Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors

Neuropharmacology

Volumn 52, Issue 2, 2007, Pages 562-575

  Ryman Rasmussen, Jessica P ^a   Griffith, Adam ^c   Oloff, Scott ^b   Vaidehi, Nagarajan ^c   Brown, Justin T ^b   Goddard III, William A ^c   Mailman, Richard B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

A 77636; Adenylate cyclase; D1 dopamine receptors; Dinapsoline; Dopamine; Functional selectivity; Receptor internalization; Receptor recycling

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; DINAPSOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INTERNALIZATION; INTRACELLULAR TRANSPORT; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY MECHANISM;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADAMANTANE; BENZOPYRANS; CELL LINE, TRANSFORMED; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; ISOQUINOLINES; METHIONINE; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; NAPHTHOLS; PROTEIN BINDING; PROTEIN TRANSPORT; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; SULFUR ISOTOPES; TIME FACTORS;

EID: 33846318470     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.08.028     Document Type: Article

References (34)

1. 1 receptor stimulation on rotation and c-fos expression. Eur. J. Pharmacol. 235 (1993) 167-168
2. I) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
3. DeNinno M.P., Schoenleber R., MacKenzie R., Britton D.R., Asin K.E., Briggs C., Trugman J.M., Ackerman M., Artman L., and Bednarz L. A68930: a potent agonist selective for the dopamine D1 receptor. Eur. J. Pharmacol. 199 (1991) 209-219
4. DeNinno M.P., Schoenleber R., Perner R.J., Lijewski L., Asin K.E., Britton D.R., MacKenzie R., and Kebabian J.W. Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor. J. Med. Chem. 34 (1991) 2561-2569
5. Garau L., Govoni S., Stefanini E., Trabucchi M., and Spano P.F. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 23 (1978) 1745-1750
6. Gardner B., Liu Z.F., Jiang D., and Sibley D.R. The role of phosphorylation/dephosphorylation in agonist-induced desensitization of D1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation. Mol. Pharmacol. 59 (2001) 310-321
7. Ghosh D., Snyder S.E., Watts V.J., Mailman R.B., and Nichols D.E. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J. Med. Chem. 39 (1996) 549-555
8. Grubbs R.A., Lewis M.M., Owens-Vance C., Gay E.A., Jassen A.K., Mailman R.B., and Nichols D.E. 8,9-Dihydroxy-1,2,3,11b-tetrahydrochromeno[4, 3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg. Med. Chem. 12 (2004) 1403-1412
9. 1 dopamine receptor agonist in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 296 (2001) 338-344
10. Harper J.F., and Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′-O-acetylation by acetic anhydride in aqueous solution. J. Cyclic Nucleotide Res. 1 (1975) 207-218
11. 1 receptor with adenylyl cyclase. J. Neurosci. 13 (1993) 2237-2248
12. Johnson K.B., Criswell H.E., Jensen K.F., Simson P.E., Mueller R.A., and Breese G.R. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 262 (1992) 855-865
13. Kebabian J.W., Britton D.R., DeNinno M.P., Perner R., Smith L., Jenner P., Schoenleber R., and Williams M. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur. J. Pharmacol. 229 (1992) 203-209
14. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
15. Kim O.J., Gardner B.R., Williams D.B., Marinec P.S., Cabrera D.M., Peters J.D., Mak C.C., Kim K.M., and Sibley D.R. The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J. Biol. Chem. 279 (2004) 7999-8010
16. Lewis M.M., Watts V.J., Lawler C.P., Nichols D.E., and Mailman R.B. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J. Pharmacol. Exp. Ther. 286 (1998) 345-353
17. 1 receptor contributes to prolonged receptor desensitization: studies with A-77636. J. Pharmacol. Exp. Ther. 276 (1996) 1022-1029
18. 2 dopamine receptors (a lesson for drug discovery). Med. Chem. Res. 13 (2004) 115-126
19. Mailman R.B., Nichols D.E., Lewis M.M., Blake B.L., and Lawler C.P. Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step. In: Jenner P., and Demirdemar R. (Eds). Dopamine Receptor Subtypes: From Basic Science to Clinical Application (1998), IOS Stockton Press 64-83
20. Mason J.N., Kozell L.B., and Neve K.A. Regulation of dopamine D-1 receptor trafficking by protein kinase A-dependent phosphorylation. Mol. Pharmacol. 61 (2002) 806-816
21. 1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J. Med. Chem. 39 (1996) 285-296
22. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., and Barak L.S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275 (2000) 17201-17210
23. Pan L., Gurevich E.V., and Gurevich V.V. The nature of the arrestin x receptor complex determines the ultimate fate of the internalized receptor. J. Biol. Chem. 278 (2003) 11623-11632
24. Ryman-Rasmussen J.P., Nichols D.E., and Mailman R.B. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol. Pharmacol. 68 (2005) 1039-1048
25. Simmons M.A. Functional selectivity, ligand-directed trafficking, conformation-specific agonism: What's in a name?. Mol. Interv. 5 (2005) 154-157
26. Tiberi M., Nash S.R., Bertrand L., Lefkowitz R.J., and Caron M.G. Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J. Biol. Chem. 271 (1996) 3771-3778
27. Trabanino R.J., Hall S.E., Vaidehi N., Floriano W.B., Kam V., and Goddard III W.A. First principles predictions of the structure and function of G-protein coupled receptors: validation for bovine rhodopsin. Biophys. J. 86 (2004) 1904-1921
28. Twentyman P.R., and Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer 56 (1987) 279-285
29. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B.K., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P., Miller K., Spedding M., and Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. (2006) epub 06/27/2006. PM:16803859
30. Vaidehi N., Floriano W.B., Trabanino R., Hall S.E., Freddolino P., Choi E.J., Zamanakos G., and Goddard III W.A. Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 99 (2002) 12622-12627
31. 1 dopamine receptor. J. Biol. Chem. 279 (2004) 37461-37469
32. Vickery R.G., and von Zastrow M. Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J. Cell Biol. 144 (1999) 31-43
33. Wyrick S., McDougald D.L., and Mailman R.B. Multiple tritium labeling of (+)-7-chloro-8-hydroxy-3-methyl-1- phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390). J. Label. Compd. Radiopharm. 23 (1986) 685-692
34. Zhang J., Barak L.S., Anborgh P.H., Laporte S.A., Caron M.G., and Ferguson S.S. Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes. J. Biol. Chem. 274 (1999) 10999-11006